L&L Biopharma Co. Ltd., Shanghai, China
- Biotech or pharma, therapeutic R&D
Phase I/II assets, LB1410 (Keytruda/anti-TIM-3 bsAb) and LB4330 (long-acting IL-10) for out-licensing.
L&L Biopharma is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of bispecific antibodies (bsAb) for treating anti-PD-1 resistant cancers.
We currently have two Phase I/II bsAb candidates available for out-licensing, with a particular interest in finding partners in the U.S.:
- LB1410: A bispecific antibody targeting both Keytruda (anti-PD-1) and Tim-3
- LB4330: An IL-10/anti-CLDN18.2 fusion protein, CD8 T cell inducer
Both LB1410 and LB4330 have received FDA IND approval. The Phase I study in China has been completed, demonstrating a good safety profile and promising efficacy. A Phase I/II study is ongoing in China.
We are currently not seeking any CROs or CDMOs at this meeting. Thanks
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}